The code of Tuoxin Pharmaceutical A shares is 301089. The issuer of the stock is Xinxiang Tuoxin Pharmaceutical Co., Ltd. The company was established on February 3, 2005 and listed on October 27, 2021. The current total market value of the stock is 4.825 billion yuan.
The company is a high-tech enterprise integrating the research, development, production and sales of chemical synthesis, biological fermentation nucleotide raw materials and pharmaceutical intermediates. It is an early-starting, large-scale and comprehensive enterprise in related fields in China, and has formed a company covering the fields of anti-viral, anti-tumor and nervous system drugs. Products are exported to countries such as India, Italy, Japan and Mexico. He has won the first prize of the Henan Province Science and Technology Progress Award and the second prize of the National Science and Technology Progress Award.
The company's main products include pharmaceutical intermediates, raw materials and other complementary drugs.
The annual revenue of pharmaceutical intermediates in 2020 was 300 million yuan, with a gross profit of 40.74%. In 2020, the revenue of raw materials for the whole year was 214 million yuan, with a gross profit of 47.05%. The full-year revenue of other complementary drugs in 2020 was 14.8684 million yuan, with a gross profit of 16.04%. Domestic revenue was 426 million yuan, with a gross profit of 41.92%, and overseas revenue was 86.7666 million yuan, with a gross profit of 50.50%.
The annual revenue of pharmaceutical intermediates in 2019 was 275 million yuan, with a gross profit of 39.79%. In 2019, the revenue from raw materials for the whole year was 110 million yuan, with a gross profit of 44.23%. The full-year revenue of other complementary drugs in 2019 was 1.2871 million yuan, with a gross profit of 73.56%. Domestic revenue was 328 million yuan, with a gross profit of 40.12%, and overseas revenue was 56.52 million yuan, with a gross profit of 46.54%.
The annual revenue of pharmaceutical intermediates in 2018 was 234 million yuan, with a gross profit of 39.79%. In 2018, the revenue from raw materials for the whole year was 156 million yuan, with a gross profit of 53.64%. In 2018, the annual revenue of other complementary medicines was 1.1549 million yuan, with a gross profit of 54.39%. Domestic revenue was 314 million yuan, with a gross profit of 44.24%, and overseas revenue was 75.7659 million yuan, with a gross profit of 49.91%.
The current number of shareholders of this stock is 36,300, the price per share is 28.82 yuan, the total share capital is 126 million shares, the circulating shares are 27,506,400, and the restricted shares are 98,493,600. This stock belongs to the biopharmaceutical industry, and its total market value ranks relatively low in this industry, ranking 69th. The company's price-to-earnings ratio, operating income and net profit also rank relatively low in the industry.